Brief: Xintela Preclinical Study Results Indicate Disease Modifying Effect Of EQSTEM
20/12/2023 15:47
Dec 20 (Reuters) - Xintela AB XINT.ST :
* PUBLISHES EFFICACY RESULTS WITH EQSTEM FROM PRECLINICAL EQUINE OA STUDY
* RESULTS DEMONSTRATE LESS PAIN, LESS CARTILAGE DAMAGE AFTER TREATMENT WITH STEM CELL
PRODUCT
EQSTEM
* RESULTS INDICATE DISEASE MODIFYING EFFECT OF EQSTEM
Source text for Eikon: ID:nMFN8394hq
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects